Immediate Impact
2 hit
Citing Papers
Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial
2021 Hit
Therapeutic pipeline in nonalcoholic steatohepatitis
2021 Hit
Works of R. Balabanska being referenced
The PanPPAR agonist lanifibranor induces both resolution of NASH and regression of fibrosis after 24 weeks of treatment in non-cirrhotic NASH: results of the NATIVE Phase 2b trial
2020